Selventa (formerly known as Genstruct) is focused on the application of computational systems biology to drug discovery and development. The company elucidates the mechanistic understanding of complex, molecular data through collaborative projects, licensed software products and the strategic development of well-differentiated pharmaceutical portfolios in a variety of disease areas. The company’s platform technology, called Systems Diagnostics (SysDxTM), is based on a “big data” analytics engine, which identifies disease-specific biomarkers through the use of proprietary algorithms that integrate a comprehensive range of complex biological information (genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medical records). Selventa’s unique ability to incorporate and analyze such information enables it to generate a clinically relevant dashboard that physicians, patients and researchers can use to make an optimal treatment decision or to stratify patient populations.

Pappas Ventures originally invested in Incellico, which was acquired by Genstruct (now Selventa) in July 2003.